We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MiroMatrix Medical Inc | NASDAQ:MIRO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.39 | 3.50 | 3.67 | 0 | 01:00:00 |
Directors and executive officers
|
| |
Number of
Shares (#) |
| |
Cash Consideration
for Shares ($) |
| |
Maximum Value of
CVRs in respect of Shares ($) |
| |||||||||
Jeffrey Ross
|
| | | | 308,775 | | | | | | 1,003,519 | | | | | | 540,356 | | |
James Douglas
|
| | | | 31,250 | | | | | | 101,563 | | | | | | 54,688 | | |
Paul Buckman
|
| | | | 52,593 | | | | | | 170,927 | | | | | | 92,038 | | |
William Burke
|
| | | | 66,943 | | | | | | 217,565 | | | | | | 117,150 | | |
John Erb
|
| | | | 56,260 | | | | | | 182,845 | | | | | | 98,455 | | |
Lisa Wipperman Heine
|
| | | | 66,943 | | | | | | 217,565 | | | | | | 117,150 | | |
Peter Maag
|
| | | | 62,092 | | | | | | 201,799 | | | | | | 108,661 | | |
All directors and current executive officers as a group (7 persons)
|
| | | | 644,856 | | | | | | 2,095,782 | | | | | | 1,128,498 | | |
Name of Executive Officer or
Director |
| |
Number of
Vested Company Stock Options (#) |
| |
Cash
Consideration for Vested Company Stock Options ($)(a) |
| |
Maximum
Value of CVRs in respect of Vested Company Stock Options ($)(b) |
| |
Number of
Unvested Company Stock Options (#) |
| |
Cash
Consideration for Unvested Company Stock Options ($)(a) |
| |
Maximum
Value of CVRs in respect of Unvested Company Stock Options ($)(b) |
| |
Number of
Unvested Company Restricted Stock Units (#) |
| |
Cash
Consideration for Unvested Company Restricted Stock Units ($)(c) |
| |
Maximum
Value of CVRs in respect of Unvested Company Restricted Stock Units ($)(b) |
| |||||||||||||||||||||||||||
Jeffrey Ross
|
| | | | 353,277 | | | | | | — | | | | | | 618,235 | | | | | | 175,000 | | | | | | — | | | | | | 306,250 | | | | | | 87,500 | | | | | | 284,375 | | | | | | 153,125 | | |
James Douglas
|
| | | | 45,000 | | | | | | — | | | | | | 78,750 | | | | | | 175,000 | | | | | | — | | | | | | 306,250 | | | | | | 20,000 | | | | | | 65,000 | | | | | | 35,000 | | |
Paul Buckman
|
| | | | 193,750 | | | | | | — | | | | | | 339,063 | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,201 | | | | | | 176,153 | | | | | | 94,852 | | |
William Burke
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 67,413 | | | | | | 219,092 | | | | | | 117,973 | | |
John Erb
|
| | | | 193,750 | | | | | | — | | | | | | 339,063 | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,201 | | | | | | 176,153 | | | | | | 94,852 | | |
Name of Executive Officer or
Director |
| |
Number of
Vested Company Stock Options (#) |
| |
Cash
Consideration for Vested Company Stock Options ($)(a) |
| |
Maximum
Value of CVRs in respect of Vested Company Stock Options ($)(b) |
| |
Number of
Unvested Company Stock Options (#) |
| |
Cash
Consideration for Unvested Company Stock Options ($)(a) |
| |
Maximum
Value of CVRs in respect of Unvested Company Stock Options ($)(b) |
| |
Number of
Unvested Company Restricted Stock Units (#) |
| |
Cash
Consideration for Unvested Company Restricted Stock Units ($)(c) |
| |
Maximum
Value of CVRs in respect of Unvested Company Restricted Stock Units ($)(b) |
| |||||||||||||||||||||||||||
Lisa Wipperman Heine
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 67,413 | | | | | | 219,092 | | | | | | 117,973 | | |
Peter Maag
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 58,368 | | | | | | 189,696 | | | | | | 102,144 | | |
All directors and current
executive officers as a group (7 persons) |
| | | | 785,777 | | | | | | — | | | | | | 1,375,111 | | | | | | 350,000 | | | | | | — | | | | | | 612,500 | | | | | | 409,096 | | | | | | 1,329,561 | | | | | | 715,919 | | |
Selected Companies
|
| |
Fully Diluted Market
Capitalization ($M) |
| |
Pricing Date
|
| |||
AN2 Therapeutics Inc.
|
| | | $ | 453 | | | |
3/24/2022
|
|
Vigil Neuroscience Inc.
|
| | | $ | 341 | | | |
1/6/2022
|
|
Rallybio Corp
|
| | | $ | 145 | | | |
7/28/2021
|
|
Longboard Pharmaceuticals Inc.
|
| | | $ | 127 | | | |
3/11/2021
|
|
Rani Therapeutics Holdings Inc.
|
| | | $ | 100 | | | |
7/29/2021
|
|
Genenta Science SpA.
|
| | | $ | 99 | | | |
12/14/2021
|
|
HCW Biologics Inc.
|
| | | $ | 65 | | | |
7/19/2021
|
|
Longeveron Inc.
|
| | | $ | 46 | | | |
2/11/2021
|
|
Gain Therapeutics Inc.
|
| | | $ | 39 | | | |
3/18/2021
|
|
In8bio Inc.
|
| | | $ | 32 | | | |
7/30/2021
|
|
MiNK Therapeutics Inc.
|
| | | $ | 31 | | | |
10/14/2021
|
|
Evaxion Biotech A/S
|
| | | $ | 23 | | | |
2/4/2021
|
|
Unicycive Therapeutics Inc.
|
| | | $ | 21 | | | |
7/13/2021
|
|
Context Therapeutics Inc.
|
| | | $ | 17 | | | |
10/19/2021
|
|
Date Announced
|
| |
Target
|
| |
Acquiror
|
| |
Upfront
Consideration ($M) |
| |
Milestone
Consideration ($M) |
| |
Equity
Value ($M) |
| |||||||||
8/9/2023
|
| |
Decibel Therapeutics
|
| |
Regeneron
|
| | | $ | 113 | | | | | $ | 99 | | | | | $ | 212 | | |
10/3/2022
|
| |
LogicBio
|
| |
AstraZeneca
|
| | | $ | 68 | | | | | | — | | | | | $ | 68 | | |
9/20/2022
|
| |
Renovacor
|
| |
Rocket Pharmaceuticals
|
| | | $ | 42 | | | | | | — | | | | | $ | 42 | | |
1/16/2020
|
| |
Neon Therapeutics
|
| |
BioNTech
|
| | | $ | 64 | | | | | | — | | | | | $ | 64 | | |
11/8/2018
|
| |
Asterias Biotheraputics
|
| |
BioTime
|
| | | $ | 84 | | | | | | — | | | | | $ | 84 | | |
7/23/2018
|
| |
TxCell
|
| |
Sangamo
|
| | | $ | 77 | | | | | | — | | | | | $ | 77 | | |
| | |
Projections (amounts in millions)
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2024
|
| |
2025
|
| |
2026
|
| |
2027
|
| |
2028
|
| |
2029
|
| |
2030
|
| |
2031
|
| |
2032
|
| |
2033
|
| ||||||||||||||||||||||||||||||
Revenue | | | | | — | | | | | | — | | | | | | — | | | | | $ | 6 | | | | | $ | 13 | | | | | $ | 114 | | | | | $ | 318 | | | | | $ | 632 | | | | | $ | 1,245 | | | | | $ | 1,679 | | |
Gross Profit
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2 | | | | | | 4 | | | | | | 85 | | | | | | 246 | | | | | | 504 | | | | | | 971 | | | | | | 1,295 | | |
Research & Development
|
| | | | (26) | | | | | | (38) | | | | | | (47) | | | | | | (25) | | | | | | (41) | | | | | | (11) | | | | | | (32) | | | | | | (63) | | | | | | (125) | | | | | | (168) | | |
Sales, General & Administrative
|
| | | | (8) | | | | | | (10) | | | | | | (10) | | | | | | (10) | | | | | | (12) | | | | | | (23) | | | | | | (64) | | | | | | (126) | | | | | | (249) | | | | | | (336) | | |
Other Operating Expenses
|
| | | | (4) | | | | | | (5) | | | | | | (5) | | | | | | (5) | | | | | | (15) | | | | | | (16) | | | | | | (30) | | | | | | (30) | | | | | | (40) | | | | | | (40) | | |
Income Tax Expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (37) | | | | | | (173) | | | | | | (233) | | |
Net Operating Profit After Tax
|
| | | $ | (38) | | | | | $ | (52) | | | | | $ | (62) | | | | | $ | (38) | | | | | $ | (64) | | | | | $ | 35 | | | | | $ | 120 | | | | | $ | 248 | | | | | $ | 384 | | | | | $ | 518 | | |
Plus: Depreciation
|
| | | | 1 | | | | | | 1 | | | | | | 1 | | | | | | 1 | | | | | | 10 | | | | | | 10 | | | | | | 10 | | | | | | 10 | | | | | | 10 | | | | | | 10 | | |
Plus: Other Non-Cash Expenses
|
| | | | 4 | | | | | | 4 | | | | | | 4 | | | | | | 4 | | | | | | 5 | | | | | | 6 | | | | | | 20 | | | | | | 20 | | | | | | 30 | | | | | | 30 | | |
Less: Capital Expenditures
|
| | | | — | | | | | | — | | | | | | — | | | | | | (100) | | | | | | — | | | | | | — | | | | | | (200) | | | | | | — | | | | | | — | | | | | | — | | |
Less: Change in Working Capital
|
| | | | 1 | | | | | | (0) | | | | | | (0) | | | | | | (0) | | | | | | (0) | | | | | | (7) | | | | | | (7) | | | | | | (10) | | | | | | (23) | | | | | | (17) | | |
Unlevered Free Cash Flow
|
| | | $ | (33) | | | | | $ | (48) | | | | | $ | (57) | | | | | $ | (133) | | | | | $ | (49) | | | | | $ | 44 | | | | | $ | (57) | | | | | $ | 268 | | | | | $ | 402 | | | | | $ | 542 | | |
| | |
Projections (amounts in millions)
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2034
|
| |
2035
|
| |
2036
|
| |
2037
|
| |
2038
|
| |
2039
|
| |
2040
|
| |
2041
|
| |
2042
|
| |||||||||||||||||||||||||||
Revenue | | | | $ | 2,105 | | | | | $ | 2,543 | | | | | $ | 2,981 | | | | | $ | 3,407 | | | | | $ | 3,845 | | | | | $ | 6,510 | | | | | $ | 7,386 | | | | | $ | 8,085 | | | | | $ | 8,660 | | |
Gross Profit
|
| | | | 1,628 | | | | | | 1,960 | | | | | | 2,288 | | | | | | 2,609 | | | | | | 2,928 | | | | | | 5,086 | | | | | | 5,738 | | | | | | 6,247 | | | | | | 6,658 | | |
Research & Development
|
| | | | (158) | | | | | | (191) | | | | | | (224) | | | | | | (255) | | | | | | (288) | | | | | | (326) | | | | | | (369) | | | | | | (404) | | | | | | (433) | | |
Sales, General & Administrative
|
| | | | (421) | | | | | | (509) | | | | | | (596) | | | | | | (681) | | | | | | (769) | | | | | | (1,302) | | | | | | (1,477) | | | | | | (1,617) | | | | | | (1,732) | | |
Other Operating
Expenses |
| | | | (50) | | | | | | (50) | | | | | | (60) | | | | | | (60) | | | | | | (60) | | | | | | (60) | | | | | | (70) | | | | | | (70) | | | | | | (80) | | |
Income Tax Expense
|
| | | | (310) | | | | | | (375) | | | | | | (437) | | | | | | (500) | | | | | | (561) | | | | | | (1,054) | | | | | | (1,185) | | | | | | (1,288) | | | | | | (1,368) | | |
Net Operating Profit After Tax
|
| | | $ | 690 | | | | | $ | 836 | | | | | $ | 972 | | | | | $ | 1,113 | | | | | $ | 1,250 | | | | | $ | 2,345 | | | | | $ | 2,637 | | | | | $ | 2,867 | | | | | $ | 3,045 | | |
Plus: Depreciation
|
| | | | 10 | | | | | | 10 | | | | | | 10 | | | | | | 10 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Plus: Other Non-Cash Expenses
|
| | | | 40 | | | | | | 40 | | | | | | 50 | | | | | | 50 | | | | | | 60 | | | | | | 60 | | | | | | 70 | | | | | | 70 | | | | | | 80 | | |
Less: Capital
Expenditures |
| | | | — | | | | | | — | | | | | | — | | | | | | (100) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Less: Change in Working Capital
|
| | | | (24) | | | | | | (18) | | | | | | (18) | | | | | | (18) | | | | | | (19) | | | | | | (126) | | | | | | (41) | | | | | | (34) | | | | | | (28) | | |
Unlevered Free Cash Flow
|
| | | $ | 716 | | | | | $ | 867 | | | | | $ | 1,013 | | | | | $ | 1,055 | | | | | $ | 1,290 | | | | | $ | 2,279 | | | | | $ | 2,666 | | | | | $ | 2,904 | | | | | $ | 3,097 | | |
Name and Principal Position
|
| |
Cash(a)
($) |
| |
Equity(b)
($) |
| |
Perquisites/Benefits(c)
($) |
| |
Total
($) |
| ||||||||||||
Jeffrey Ross
|
| | | | 572,000 | | | | | | 743,750 | | | | | | 18,000 | | | | | | 1,333,750 | | |
James Douglas
|
| | | | 201,500 | | | | | | 406,250 | | | | | | 9,000 | | | | | | 616,750 | | |
Name and Principal Position
|
| |
Maximum Value of
CVRs in respect of Shares Underlying Unvested Company Options ($) |
| |
Cash Consideration
and Maximum Value of CVRs in respect of Shares Underlying Unvested Company RSUs ($) |
| ||||||
Jeffrey Ross
|
| | | | 306,250 | | | | | | 437,500 | | |
James Douglas
|
| | | | 306,250 | | | | | | 100,000 | | |
| Dated: November 13, 2023 | | |
MIROMATRIX MEDICAL INC.
|
| ||||||
| | | | By: | | |
/s/ James Douglas
|
| |||
| | | | | | | Name: | | | James Douglas | |
| | | | | | | Title: | | | Chief Financial Officer | |
|
|
| |
|
|
|
PIPER SANDLER & CO.
October 29, 2023 |
| | ||
|
Board of Directors
Miromatrix Medical Inc. 6455 Flying Cloud Drive, Suite 107 Eden Prairie, MN 55344 |
| |
1 Year MiroMatrix Medical Chart |
1 Month MiroMatrix Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions